14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:DRNA
Delisted

Dicerna Pharmaceuticals Stock Price (Quote)

$38.22
+0 (+0%)
At Close: May 27, 2022

Range Low Price High Price Comment
30 days $38.22 $38.22 Friday, 27th May 2022 DRNA stock ended at $38.22. During the day the stock fluctuated 0% from a day low at $38.22 to a day high of $38.22.
90 days $38.22 $38.22
52 weeks $19.06 $40.14

Historical Dicerna Pharmaceuticals prices

Date Open High Low Close Volume
Jun 07, 2019 $12.81 $13.25 $12.50 $12.92 540 936
Jun 06, 2019 $12.60 $12.79 $12.45 $12.72 474 000
Jun 05, 2019 $12.54 $12.67 $12.19 $12.60 286 877
Jun 04, 2019 $12.31 $12.48 $12.17 $12.39 481 722
Jun 03, 2019 $12.25 $12.46 $11.86 $12.12 437 767
May 31, 2019 $12.52 $12.92 $12.32 $12.38 532 682
May 30, 2019 $12.60 $12.82 $12.41 $12.76 397 224
May 29, 2019 $12.29 $13.11 $12.21 $12.57 615 093
May 28, 2019 $12.50 $13.39 $12.35 $12.45 522 606
May 24, 2019 $12.14 $12.67 $12.00 $12.49 650 160
May 23, 2019 $11.46 $11.86 $11.11 $11.83 275 002
May 22, 2019 $11.86 $12.01 $11.50 $11.60 200 920
May 21, 2019 $11.97 $12.20 $11.81 $11.89 347 079
May 20, 2019 $11.84 $12.43 $11.65 $11.92 721 695
May 17, 2019 $11.59 $12.66 $11.51 $12.10 531 555
May 16, 2019 $11.59 $11.88 $11.44 $11.74 443 752
May 15, 2019 $11.06 $11.45 $10.89 $11.40 296 556
May 14, 2019 $10.90 $11.70 $10.87 $11.24 542 273
May 13, 2019 $11.00 $11.29 $10.70 $10.78 637 678
May 10, 2019 $11.88 $12.29 $10.91 $11.39 613 202
May 09, 2019 $12.29 $12.52 $11.88 $12.14 771 971
May 08, 2019 $12.36 $12.85 $12.22 $12.48 192 399
May 07, 2019 $13.15 $13.26 $12.28 $12.37 308 324
May 06, 2019 $12.80 $13.47 $12.80 $13.32 388 723
May 03, 2019 $12.76 $13.10 $12.55 $13.09 285 527
Click to get the best stock tips daily for free!

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for liver diseases and cancers based on a proprietary RNA interference technology platform in the United States and internationally. The company’s development programs include DCR-PH1 for the treatment of primary hyperoxaluria type 1 (PH1) through targeting the gene encoding the liver enzyme glycolate oxidase; and other rare inherit... DRNA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT